Citigroup: Time To Buy Inovio Pharmaceuticals (NASDAQ:INO)? Has $10.0 Valuation Target

December 7, 2017 - By Stephen Andrade

 Citigroup: Time To Buy Inovio Pharmaceuticals (NASDAQ:INO)? Has $10.0 Valuation Target

Why Has Citigroup Given Inovio Pharmaceuticals (NASDAQ:INO) a $10.0 Price Target

Investment firm Citigroup has today began coverage on Inovio Pharmaceuticals (NASDAQ:INO) shares, with a Buy rating, while giving it the price target at $10.0.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Ratings Coverage

Among 8 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals has $31 highest and $9 lowest target. $14.33’s average target is 227.17% above currents $4.38 stock price. Inovio Pharmaceuticals had 34 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Hold” rating by Zacks on Wednesday, August 12. Maxim Group maintained Inovio Pharmaceuticals, Inc. (NASDAQ:INO) rating on Wednesday, September 9. Maxim Group has “Buy” rating and $23 target. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, August 8. PiperJaffray downgraded it to “Neutral” rating and $9 target in Thursday, March 16 report. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, November 9. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 9. The firm has “Buy” rating by Stifel Nicolaus given on Monday, June 26. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, October 5 report. The stock has “Buy” rating by Maxim Group on Thursday, June 8. H.C. Wainwright maintained the shares of INO in report on Thursday, May 25 with “Buy” rating.

It closed at $4.38 lastly. It is down 29.01% since December 7, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Analysts await Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report earnings on March, 21. They expect $-0.29 EPS, up 19.44 % or $0.07 from last year’s $-0.36 per share. After $-0.40 actual EPS reported by Inovio Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.50 % EPS growth.

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company has market cap of $395.50 million. The Company’s SynCon immunotherapy design has the ability to break the immune systemÂ’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It currently has negative earnings. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, Ebola, Middle East Respiratory Syndrome, and Zika virus.

More recent Inovio Pharmaceuticals, Inc. (NASDAQ:INO) news were published by: Fool.com which released: “Why Inovio Pharmaceuticals Inc. Is Sinking Today” on November 09, 2017. Also Globenewswire.com published the news titled: “Inovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors” on December 06, 2017. Globenewswire.com‘s news article titled: “Inovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with …” with publication date: November 27, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.